Drug allergy
- PMID: 39844329
- PMCID: PMC11755868
- DOI: 10.1186/s13223-024-00936-1
Drug allergy
Abstract
Drug allergy encompasses a spectrum of immunologically-mediated hypersensitivity reactions (HSRs) with varying mechanisms and clinical presentations. This type of adverse drug reaction (ADR) not only affects patient quality of life, but may also lead to delayed treatment, unnecessary investigations, and increased morbidity and mortality. Given the spectrum of symptoms associated with the condition, diagnosis can be challenging. Therefore, referral to an allergist experienced in the diagnosis and management of drug allergy is recommended if a drug-induced allergic reaction is suspected. Diagnosis relies on a careful history and physical examination and, in some instances, skin testing or in vitro testing and drug challenges. The most effective strategy for the management of allergist-confirmed drug allergy is avoidance or discontinuation of the offending drug. When available, alternative medications with unrelated chemical structures should be substituted. Cross-reactivity among drugs should also be taken into consideration when choosing alternative agents. Additional therapy for drug HSRs may include topical corticosteroids, oral antihistamines and, in severe cases, systemic corticosteroids and other immunomodulators. In the event of anaphylaxis, the treatment of choice is intramuscular epinephrine. If a patient with a history of anaphylaxis requires a specific drug and there is no acceptable alternative, desensitization to that drug may be considered. This article provides a background on drug allergy and strategies for the diagnosis and management of some of the most common drug-induced allergic reactions.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: Dr. Samira Jeimy has received consulting fees and honoraria from Sanofi, GSK, ALK, AstraZeneca, Medexus, Stallergenes Greer and Novartis. Dr. Moshe Ben-Shoshan has received consulting fees from Novartis and Sanofi. Dr. Anne K. Ellis has participated in advisory boards for AstraZeneca. ALK Abello, Bausch, Circassia Ltd, GlaxoSmithKline, Merck and Novartis, and has been a speaker for ALK Abellos, AstraZeneca, Mylan, Merck, Novartis, Pfizer, Sanofi, Regeneron and Takeda. Her institution has received research grants from Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Sanofi and Regeneron. Dr. Ellis is also a former consultant to ALK-Abello Canada and Bayer Consumer Health Division. Dr. Ghislaine A.C. Isabwe, Dr. Ana Maria Copaescu and Dr. Tiffany Wong have no competing interests to disclose.
Figures
References
-
- Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2010;125:S126–37. - PubMed
-
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9. - PubMed
-
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5. - PubMed
-
- Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–64. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
